keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/29348424/intraocular-inflammatory-cytokines-in-patients-with-neovascular-age-related-macular-degeneration-before-and-after-initiation-of-intravitreal-injection-of-anti-vegf-inhibitor
#1
Tomohito Sato, Masaru Takeuchi, Yoko Karasawa, Toshio Enoki, Masataka Ito
Age-related macular degeneration (AMD) is a cause of blindness in people older than 50 years. Accumulating evidence indicates the involvement of systemic and local inflammation in the pathogenesis and progression of AMD. Aflibercept is an anti-vascular endothelial growth factor (VEGF) inhibitor, and intravitreal injection of aflibercept (IVA) is the approved treatments of neovascular AMD (nAMD), but the effect on inflammatory response remains unclear. The aim of our study was to investigate the profiles of inflammatory cytokines in the aqueous humor of nAMD patients before and after initiation of IVA...
January 18, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29344488/intravitreal-aflibercept-as-rescue-therapy-for-post-radiation-cystoid-macular-edema-resistant-to-intravitreal-bevacizumab-outcomes-at-1-year
#2
Mohammed Ali Khan, Arman Mashayekhi, Jerry A Shields, Carol L Shields
Background/Aims: To investigate the efficacy of intravitreal aflibercept as rescue therapy for post-radiation cystoid macular edema (CME) resistant to prior treatment with intravitreal bevacizumab (IVB). Methods: Retrospective, interventional, case-controlled series. Eyes with persistent post-radiation CME were treated with intravitreal aflibercept (2 mg/0.05 mL). Central macular thickness (CMT) and visual acuity were compared to a matched control group treated with only IVB at 1 year...
November 2017: Ocular Oncology and Pathology
https://www.readbyqxmd.com/read/29343970/a-retrospective-examination-of-the-us-food-and-drug-administration-s-clinical-pharmacology-reviews-of-oncology-biologics-for-potential-use-of-therapeutic-drug-monitoring
#3
Brett Fleisher, Sihem Ait-Oudhia
Background: Biologics have gained traction for use in oncology, but have demonstrate clinical variability for efficacy and safety. Therapeutic drug monitoring (TDM) can benefit patients' outcomes from a biologic therapy when the latter has a defined therapeutic window. A clinically relevant therapeutic window may exist for biologics with established exposure-response (E-R) relationships for efficacy and/or safety and a documented maximum tolerated dose (MTD). Additionally, the inter-individual variability (IIV) on the clearance (CL) parameter could determine risks for patients falling outside the proposed therapeutic window...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29336897/the-real-world-effect-of-intravitreous-anti-vascular-endothelial-growth-factor-drugs-on-intraocular-pressure-an-analysis-using-the-iris-registry
#4
Elizabeth A Atchison, Kevin M Wood, Cynthia G Mattox, Catherine N Barry, Flora Lum, Mathew W MacCumber
PURPOSE: To identify sustained differences in intraocular pressure (IOP) after intravitreous injections of anti-vascular endothelial growth factor (VEGF) drugs. DESIGN: Database study. PARTICIPANTS: Patients seeing an ophthalmic provider who contributes to the database. METHODS: We identified a total of 23 776 unique patients who received only a single type of anti-VEGF medication (bevacizumab, aflibercept, or ranibizumab) by injection in the right eye in the American Academy of Ophthalmology Intelligent Research in Sight Registry...
January 11, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29326855/all-types-of-age-related-macular-degeneration-in-one-patient
#5
Zafer Cebeci, Nur Kır
Herein, we describe a neovascular age-related macular degeneration patient with retinal angiomatous proliferation (RAP) and polypoidal choroidal vasculopathy (PCV) coexisting in the same eye at the time of diagnosis. A 55-year-old woman presented with a history of decreased vision in her left eye. Fundoscopy, fluorescein and indocyanine green angiography, and optical coherence tomography imaging revealed RAP and PCV lesions in her left eye at first diagnosis. The patient received intravitreal ranibizumab therapy but developed tachyphylaxis after the first dose despite having three monthly doses...
December 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/29324624/intravitreal-aflibercept-in-the-treatment-of-polypoidal-choroidal-vasculopathy-associated-with-morning-glory-syndrome
#6
Claudio Iovino, Maurizio Fossarello, Enrico Peiretti
PURPOSE: To describe an unusual case of polypoidal choroidal vasculopathy secondary to morning glory syndrome successfully treated with three aflibercept intravitreal injections. METHODS: Case report. RESULTS: A 68-year-old white man presented with a 2-month history of diminished vision of his left eye. Fundus examination showed a morning glory syndrome disk anomaly with some perimacular subretinal hemorrhages and lipid depositions. Fundus autofluorescence, fluorescein and green indocyanine angiography, spectral domain optical coherence tomography, and optical coherence tomography angiography were performed and confirmed the presence of a juxtapapillary polypoidal choroidal vasculopathy with intraretinal and subretinal fluid...
January 10, 2018: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29324593/incidence-and-long-term-visual-acuity-outcomes-of-retinal-pigment-epithelium-tears-after-intravitreal-anti-vascular-endothelial-growth-factor-treatment-of-neovascular-age-related-macular-degeneration
#7
Clara Vazquez-Alfageme, Luke Nicholson, Robin D Hamilton, Praveen J Patel
PURPOSE: To report the incidence of retinal pigment epithelium tears in eyes treated with aflibercept for neovascular age-related macular degeneration and compare it with ranibizumab, and to describe long-term visual outcomes of retinal pigment epithelium tears after intensive anti-vascular endothelial growth factor treatment. METHODS: Retrospective analysis of clinical charts, spectral domain optical coherence tomography and fundus fluorescein angiography imaging of consecutive naive patients treated with intravitreal aflibercept or ranibizumab for neovascular age-related macular degeneration...
January 10, 2018: Retina
https://www.readbyqxmd.com/read/29317400/two-year-outcomes-of-intravitreal-ziv-aflibercept
#8
Ahmad M Mansour, Mohammed Ashraf, Abdulrazzak Charbaji, Muhammad H Younis, Ahmed A Souka, Avantika Dogra, Hana A Mansour, Jay Chhablani
AIM: To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. METHODS: Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography...
January 9, 2018: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29311612/benefits-of-aflibercept-treatment-for-age-related-macular-degeneration-patients-with-good-best-corrected-visual-acuity-at-baseline
#9
Sakiko Minami, Norihiro Nagai, Misa Suzuki, Toshihide Kurihara, Hideki Sonobe, Mamoru Kamoshita, Atsuro Uchida, Hajime Shinoda, Hitoshi Takagi, Shozo Sonoda, Taiji Sakamoto, Kazuo Tsubota, Yoko Ozawa
Currently, age-related macular degeneration (AMD) is treated while patients exhibit good best-corrected visual acuity (BCVA). However, previous clinical trials only include patients with poor BCVA. We prospectively analyzed the benefits of intravitreal aflibercept (IVA) treatment for AMD patients exhibiting good BCVA at baseline. Twenty-nine treatment-naive AMD patients (29 eyes) with BCVA better than 0.6 (74 letters in ETDRS chart) were treated with IVA once a month for 3 months and every 2 months thereafter with no additional treatments...
January 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29290015/changes-in-systemic-vascular-endothelial-growth-factor-levels-after-intravitreal-injection-of-aflibercept-in-infants-with-retinopathy-of-prematurity
#10
Chung-Ying Huang, Reyin Lien, Nan-Kai Wang, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang, Chi-Chun Lai, Wei-Chi Wu
BACKGROUND: To investigate the levels of VEGF in the systemic circulation of patients with type 1 ROP who received intravitreal injections of 1 mg (0.025 mL) aflibercept (IVA) or 0.625 mg (0.025 mL) bevacizumab (IVB). METHODS: Patients who had type 1 ROP and received either IVA or IVB were enrolled in this prospective study. Serum and plasma samples were collected prior to and up to 12 weeks after IVB or IVA treatment. The serum and plasma VEGF levels were measured using enzyme-linked immunosorbent assays (ELISAs), and the platelet levels in the blood were also quantified...
December 30, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29280940/changes-in-plasma-vascular-endothelial-growth-factor-level-after-intravitreal-injection-of-bevacizumab-aflibercept-or-ranibizumab-for-diabetic-macular-edema
#11
Takao Hirano, Yuichi Toriyama, Yasuhiro Iesato, Akira Imai, Toshinori Murata
PURPOSE: The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) and after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for treatment of DME. METHODS: Plasma VEGF level was evaluated in 72 patients with DR and changes were measured in 42 patients with DME receiving intravitreal injections of bevacizumab, aflibercept, or ranibizumab at the initial injection...
December 21, 2017: Retina
https://www.readbyqxmd.com/read/29280937/efficacy-and-safety-of-intravitreal-aflibercept-and-ranibizumab-in-asian-patients-with-neovascular-age-related-macular-degeneration-subgroup-analyses-from-the-view-trials
#12
Tien Yin Wong, Chui Ming Gemmy Cheung, Timothy Y Y Lai, Shih-Jen Chen, Won Ki Lee, Young Hee Yoon, Tomohiro Iida, Claudia Tueckmantel, Olaf Sowade, Yuichiro Ogura
PURPOSE: To assess the treatment effect of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration. METHODS: We evaluated data from VIEW 1 and VIEW 2, comparing functional and morphologic outcomes at Week 96 between intravitreal aflibercept 2 mg monthly (2q4) or 2 mg bimonthly after 3 initial monthly doses (2q8) versus ranibizumab 0.5 mg monthly among Asian patients (n = 269) and between Asian and white patients (n = 2044)...
December 26, 2017: Retina
https://www.readbyqxmd.com/read/29274022/outcome-of-treat-and-monitor-regimen-of-aflibercept-and-ranibizumab-in-macular-edema-secondary-to-non-ischemic-branch-retinal-vein-occlusion
#13
Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky
PURPOSE: To compare the efficacy of a modified PRN treatment regimen ("treat and monitor") of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. METHODS: Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a "treat and monitor" treatment regimen with monthly follow-up for 12 months...
December 22, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29260119/one-year-outcomes-of-ziv-aflibercept-for-macular-edema-in-central-retinal-vein-occlusion
#14
Mohab Eldeeb, Errol W Chan, Chintan J Dedhia, Ahmad Mansour, Jay Chhablani
Purpose: To report the 12-month efficacy and safety outcomes of intravitreal ziv-aflibercept in macular edema secondary to central retinal vein occlusion (CRVO). Methods: Interventional case series documenting 12-month outcomes of intravitreal ziv-aflibercept (1.25 mg in 0.05 mL) in 6 patients with treatment-naive macular edema secondary to CRVO. All patients had comprehensive ophthalmic examination, spectral domain optical coherence tomography at baseline and all follow-up visits, and fluorescein...
December 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29240306/diabetic-macular-oedema-treated-with-intravitreal-anti-vascular-endothelial-growth-factor-2-4%C3%A2-years-follow-up-of-visual-acuity-and-retinal-thickness-in-566-patients-following-danish-national-guidelines
#15
Delila Hodzic-Hadzibegovic, Birgit Agnes Sander, Tine Juul Monberg, Michael Larsen, Henrik Lund-Andersen
PURPOSE: To investigate long-term functional and anatomical outcomes, discontinuation patterns, drug switching and rates of nonimprovement in patients treated with ranibizumab pro re nata (PRN) regimen for diabetic macular oedema (DME) according to the Danish national guidelines. METHODS: Retrospective cohort study of 566 eyes in 566 patients with centre-involved DME who started intravitreal treatment with ranibizumab between January 2011 and December 2013 in the Greater Copenhagen region...
December 14, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29240298/diabetic-macular-edema-innovative-technologies-and-economic-impact-new-opportunities-for-the-lombardy-region-healthcare-system
#16
Emanuela Foglia, Lucrezia Ferrario, Francesco Bandello, Camilla Ferri, Innocente Figini, Michela Franzin, Gianpiera Gambaro, Ugo Introini, Massimo Medaglia, Giovanni Staurenghi, Patrizia Tadini, Andrea Fomiatti, Davide Croce
PURPOSE: Diabetic macular edema (DME) is a leading cause of vision loss and blindness. The aim of this study was to evaluate the economic benefits of introducing additional alternative technologies (Dexamethasone intravitreal implant - DEX - and Aflibercept injections), compared with the historical scenario of Ranibizumab intravitreal injections. METHODS: A 3-year budget impact model was developed, taking into consideration the perspective of the Lombardy Region Healthcare Service (LRHS)...
December 14, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29234221/aflibercept-in-macular-edema-secondary-to-retinal-vein-occlusion-a-real-life-study
#17
Abdullah Ozkaya, Beril Tulu, Ruveyde Garip
Purpose: To evaluate the real life outcomes of intravitreal aflibercept (IVAfl) treatment in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) during the first year of treatment. Methods: Retrospective case series. Newly diagnosed or persistent ME patients secondary to RVO who were treated with IVAfl and had a follow-up period of at least 12 months were included. Twenty-two patients (54.8%) received 3 loading month loading doses IVAfl initially, whereas 20 patients (45...
October 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/29232758/-time-course-of-changes-in-visual-acuity-after-a-single-injection-of-aflibercept-or-ranibizumab-in-neovascular-age-related-macular-degeneration-analysis-of-aggregated-real-life-data
#18
Robert G H Wilke, Robert Patrick Finger, Helmut G Sachs
Background Treatment of neovascular age-related macular degeneration (nvAMD) under real life conditions may differ from controlled prospective trials with respect to the number of injections and long term preservation of visual acuity. In many instances, intervals for controls and re-injection cannot be maintained as frequently as required. This case series examines actual intervals for control and re-injection visits, in order to estimate how prolonged intervals have an impact on momentary visual acuity and how long term visual outcome is affected...
December 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29232334/intravitreal-ziv-aflibercept-for-neovascular-age-related-macular-degeneration-52-week-results
#19
João R de Oliveira Dias, Gabriel Costa de Andrade, Vinicius F Kniggendorf, Eduardo A Novais, Vítor K L Takahashi, André Maia, Carsten Meyer, Sung E S Watanabe, Michel E Farah, Eduardo B Rodrigues
PURPOSE: To evaluate the 52-week safety and efficacy of intravitreal ziv-aflibercept in patients with neovascular age-related macular degeneration. METHODS: All patients received three monthly intravitreal injections of 0.05 mL of ziv-aflibercept (1.25 mg) followed by a pro re nata regimen. The best-corrected visual acuity and spectral domain optical coherence tomography were obtained at baseline and monthly. Full-field and multifocal electroretinograms were obtained at baseline and 4, 13, 26, and 52 weeks...
December 11, 2017: Retina
https://www.readbyqxmd.com/read/29220114/treat-and-extend-versus-every-other-month-regimens-with-aflibercept-in-age-related-macular-degeneration
#20
Akira Haga, Takahiro Kawaji, Ryuichi Ideta, Yasuya Inomata, Hidenobu Tanihara
PURPOSE: To compare the 1-year outcomes of treat-and-extend (TAE) and every-other-month (2M) regimens with intravitreal aflibercept in Japanese wet age-related macular degeneration (AMD) patients. METHODS: Prospective, multicenter, randomized clinical trial. The primary outcome measure was the proportion of eyes in which the best-corrected visual acuity (BCVA) was maintained at week 52 [with a loss of <0.3 logarithm of minimum angular of resolution (logMAR) units]...
December 8, 2017: Acta Ophthalmologica
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"